Actin filament reorganization in HL-60 leukemia cell line after treatment with G-CSF and GM-CSF. by Grzanka, Alina et al.
Introduction
Proliferation and differentiation of hematopoietic cells
into granulocyte or monocyte lineages is regulated by
the family of pleiotropic cytokines, known as colony-
stimulating factors (CSFs), that act as stimulants
through the specific cell surface receptors [1-3]. 
Granulocyte-colony stimulating factor (G-CSF) is a
glycoprotein secreted by the stromal cells of the
hematopoietic organs that promotes proliferation and
differentiation of granulocytic progenitor cells. More-
over, G-CSF regulates functions and the survival of
mature granulocytes [4]. The G-CSF receptor is
expressed on myeloid progenitors and mature neu-
trophil granulocytes [5]. Binding of G-CSF to its
receptor inhibits apoptosis and induces proliferation
and differentiation of hematopoietic cells into
neuthrophil lineage cells [6,7]. G-CSF enhances
chemotaxis, motility and phagocytosis of mature
neuthrophils [8]. 
The cytokine regulates various stem cell activities,
phagocyte functions and cytotoxicity of monocytes or
macrophages, and modulates antigen presentation on
surface of immune cells [5]. It induces differentiation
along the granulocyte, monocyte, megakaryocyte or
erythrocyte lineage. GM-CSF also affects the mature
cell effector functions, such as oxidative burst, intra-
cellular killing, and cytokine release [9,10]. GM-CSF
receptor is expressed more widely along blood cells
than G-CSF receptor. It is present on bone marrow
stem cells, erythroid and megakaryocyte precursors,
monocytes, macrophages, mature neuthrophils and
dendritic cells [11,12]. Soluble GM-CSF receptor pro-
tein has been identified in vivo [13]. In vitro, GM-CSF
enhances proliferation of early stem cells and pro-
motes the formation of colonies containing mixtures of
granulocytes, eosinophils and macrophages [14]. 
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There is also considerable evidence that altered 
G-CSF and GM-CSF signaling pathways may play a
role in leukemogenesis by providing the leukemic
cells with proliferative advantage or blocking granulo-
cytic differentiation [15,16].
G-CSF and GM-CSF have been used in the treatment
of acute myelogenous leukemia (AML). They shorten
the time of neutropenia, reduce susceptibility to infec-
tions, decrease length of hospitalization and increase sus-
ceptibility of the blasts to chemotherapy drugs [17].
Growth factors induce maturation and proliferation of
pluripotential bone marrow stem cells [18]. In the treat-
ment of neoplastic diseases, the main problem is a dam-
age of the bone marrow caused by chemotherapy or
radiotherapy. Cytokines, like GM-CSF, are able to
induce proliferation and maturation of immature
myeloid progenitor cells and prime mature cell functions
in phagocytes [19]. The use of hematopoietic growth
factors is also one of the most promising areas of
research in allogeneic marrow transplantation. More-
over, there are studies on the application of growth fac-
tors in harvesting stem cells available for transplantation.
Certain growth factors were also found to stimulate the
growth and function of a variety of nonhematopoietic
cells, such as non-small cell lung carcinoma and ovarian
carcinoma cell lines and other cell lines [5,20-22].
At present, it is poorly understood how these two
important hematopoietic growth factors acting during
the G1 phase of the cell cycle drive cells into S phase
through binding to their cell surface receptors, which in
turn affect cytoskeletal proteins. As shown by Leung et
al. [23], the cytoskeleton is involved in modulating sig-
nal transduction, as well as structural changes accompa-
nying proliferation and differentiation processes.
According to Bissel et al. [24], some extracellular fac-
tors via transmembrane receptors can influence the
geometry of the cytoskeleton, what, in turn, could mod-
ulate its interactions with mRNA and consequently
cause alterations of gene expression patterns.
HL-60 is p53-null human acute leukemia cell line
consisting predominantly of promieloid cells, which
may differentiate into mature granulocytes sponta-
neously or can be induced to differentiate by incuba-
tion with certain factors such as: G-CSF, GM-CSF,
retinoic acid, vitamin D3 [25-28].
The aim of this study was to investigate the
rearrangement of F-actin in human leukemic cell line
HL-60 after treatment with G-CSF and GM-CSF,
using fluorescence microscopy and flow cytometry.
Materials and methods
Cell culture. The human promyelomonocyte leukemic HL-60
(ATCC CCL 240) cells were diluted to density of 1×105 /ml and
grown at 37°C in a 5% CO2 atmosphere in RPMI 1640 medium
supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(FBS) and 50 μg/ml gentamycin. 
Growth factors. The HL-60 cells were cultured in the presence of
12 ng/ml human non-glycosylated G-CSF (Sigma-Aldrich, St.
Louis, Missouri, USA) and 12 ng/ml human GM-CSF (Sigma-
Aldrich, St. Louis, Missouri, USA) for 72 hours in separate exper-
iments for each growth factor. Control cells were grown under
identical conditions, but in the absence of growth factors. Cell via-
bility was assessed by the trypan blue dye exclusion method. The
experiment was repeated 10 times (independent analyses).
Fluorescence. Cells treated with cytokines, as well as control cells
were fixed for 20 min with 4% paraformaldehyde in PBS at 4°C
and cytocentrifuged onto glass slides. Fixed cells were then per-
meabilized by incubation with 0.1 % Triton X-100 for 3 min.
Fixed and permeabilized cells were incubated at room temper-
ature with phallacidin conjugated to BODIPY (Molecular Probes,
Eugene, Oregon, USA) for 20 min. Nuclear DNA was counter-
stained using 4',6-diamidino-2-phenyloindole (DAPI) (Sigma-
Aldrich, St. Louis, Missouri, USA), rinsed and mounted in Gelvatol.
F-actin and DNA organization were examined using an Eclipse
E600 microscope equipped with an Y-FL epifluorescent attach-
ment (Nikon, Tokyo, Japan). 
Cell cycle analysis. For the cell cycle analysis, HL-60 cells were
stained with hypotonic propidium iodide solution (20 μg/ml;
DNA-Prep Kit, Sigma-Aldrich, St. Louis, Missouri, USA) and
then analyzed using Epics XL flow cytometer.
Apoptosis. Apoptosis was analyzed, using the Annexin V-FITC
Apoptosis Detection Kit (BD Pharmingen, San Diego, CA, USA).
This assay was performed according to the manufacturer's instruc-
tion.
F-actin content. Cells were fixed with 4% paraformaldehyde for
20 min at 4°C, rinsed with PBS and permeabilized with 0.1 % Tri-
ton X-100 for 3 min. After washing in PBS, cells were stained with
BODIPY-phallacidin (Molecular Probes, Eugene, Oregon, USA)
20 min at room temperature. Stained samples were analyzed in an
Epics XL flow cytometer.
Statistical analysis. Statistical analysis was performed using the
STATISTICA 6.0 for Windows, StatSoft software (Tulsa, OK,
USA). All comparisons based on ANOVA Repeated Measures
Designs and were presented as Duncan's test results.
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Fig. 1. F-actin labeling in control cells; after fixation and perme-
abilization of cells, F-actin was stained for fluorescence
microscopy by incubation with BODIPY-phallacidin. Fluores-
cence labeling mainly around the cell periphery, scant signals in
the cytoplasm are seen. Bar - 50 µm.
Results
Stimulation of cell differentiation with granulocyte-
colony stimulating factor (G-CSF) and granulocyte-
macrophage colony stimulating factor (GM-CSF)
resulted in changes including reorganization of the
actin cytoskeleton. F-actin labeling was generally
intense, but some cells with weaker labeling of F-actin
were occasionally seen. In HL-60 control cells, F-actin
was rather regularly arranged in the form of a ring
around the cell periphery, but some diffuse, less
intense fluorescence was also observed throughout the
cytoplasm (Fig. 1).  
Fluorescence labeling of F-actin in HL-60 cells
treated with G-CSF showed higher fluorescence inten-
sity inside the whole cell area compared to control. In
most of these cells, F-actin formed small aggregates in
the cytoplasm, but some cells with the network of F-
actin were seen, as well as cells with both forms of
actin organization, i.e. cytoplasmic aggregates and the
network (Fig. 2a, 2b and 2c). As shown by DAPI stain-
ing, only very few nuclei from these cells displayed
apoptotic features (Fig. 2d).     
The main characteristic of GM-CSF treated cells
was a bright fluorescent pattern of F-actin labeling in
form of the network. There was also more abundant F-
actin distribution around the plasma membrane com-
pared to G-CSF-treated cells. In some cases relatively
few F-actin aggregates diffusely distributed through-
out the cell were also seen (Fig. 3a and 3b). In contrast
to G-CSF-treated HL-60 cells, after treatment with
GM-CSF differences in the cell size were observed.
Thus, there seem to be a correlation between the effect
of GM-CSF on HL-60 cells and an increase in the
number of giant cells with the large nucleus (Fig. 4a
and 4b). Both agents also caused an apperance of some
F-actin aggregates around the plasma membrane. 
Our morphological observations of F-actin
rearrangements in HL-60 cells treated with cytokines
were supported by the quantitative changes in the rate
of actin polymerization (Fig. 5 and 6). Despite of
that, differences in the mean fluorescence intensity,
as indicated by the flow cytometry assay, were not
statistically significant. Moreover, cytophotometric
analysis of the cell cycle showed that both cytokines
caused the transition from G1- into the S-phase of the
cell cycle for the majority of studied cells. In agree-
ment with statistical significance criteria (Duncan's
test), there was a decrease in the population of cells in
G1 phase, as well as an increase in the number of cells
in S-phase compared with control (p<0.05), (Fig. 7).
Further proof for the stimulating rather than pro-apop-
totic activity of both agents used, came from the
annexin V assay for flow cytometry, which revealed
that 1.86% and 2.88% of total cell number (mean value
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Fig. 2. Cells treated with G-CSF; F-actin was stained for fluorescence microscopy with BODIPY-phallacidin, nuclei were counterstained
with DAPI. a-c. F-actin labeling in cells. Visible mainly aggregates and, less abundant, the network; d. Nuclei of G-CSF-treated cells were
stained with DAPI, only few cells displaying some apoptotic features are seen. Bar - 50 µm.
per 10 biologically and experimentally independent
analyses) had some apoptotic features in case of G-
CSF and GM-CSF treatment, respectively. These
results were only slightly higher than those obtained
for apoptotic control cells, which represented 1.17% of
total cell number in control conditions (Fig. 8).    
Discussion
In the present work, we studied the pattern of actin dis-
tribution in HL-60 leukemic cells after treatment
with GM-CSF or G-CSF. The results show that stim-
ulation of this cell line with G-CSF and GM-CSF
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Fig. 3. F-actin labeling in cells under treatment with GM-CSF; F-actin was stained for fluorescence microscopy with BODIPY-phal-
lacidin. Visible mainly F-actin network, less abundant granules. Bar - 50 µm.
Fig. 4. Giant cells with the large nucleus were observed under GM-CSF treatment; F-actin was stained for fluorescence microscopy with
BODIPY-phallacidin, nuclei were counterstained with DAPI. a. Fluorescent F-actin labeling; b. DAPI staining. Bar - 50 µm.
caused F-actin reorganization, including the formation
of three-dimensional network. There were also bright
conglomerations of F-actin not only in the cytoplasm,
but also at the cell surface. We belive that these sur-
face-associated structures may represent an initial
stage in apoptotic blebs formation. Currently, we have
observed only slightly increasing rate of actin poly-
merization (reflected by the mean fluorescence inten-
sity), after exposure to differentiation-stimulating fac-
tors. The considerably higher level of F-actin in the
cell was shown by Gomez-Cambronero et al. [29] and
Carulli et al. [30] as a result of GM-CSF and G-CSF
treatment, respectively. The same effect of GM-CSF
on actin polymerization was noticed by Chodniewicz
and Zhelev [31]. On the other hand, Kutsuna et al. [32]
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Fig. 5. Influence of GM-CSF and G-CSF over F-actin content
revealed by mean fluorescence intensity compared to control.
After F-actin labeling with BODIPY-phallacidin, fluorescence
intensity was analysed using an Epics XL flow cytometer. Error
bars indicate standard deviation (SD) from the mean.
Fig. 6. Representative flow cytometric analysis of F-actin content
in HL-60 cells after cytokine treatment. After F-actin labeling with
BODIPY-phallacidin, fluorescence intensity was analysed using
an Epics XL flow cytometer.
Fig. 7. Differences in the percentage of HL-60 cells in each phase
of the cell cycle under influence of G-CSF and GM-CSF in com-
parison with control. Cells stained with propidium iodide solution
were analysed by flow cytometry. Error bars indicate standard
deviation (SD) from the mean.
Fig. 8. Differences in the percentage of apoptotic cells under influ-
ence of G-CSF and GM-CSF in comparison with control. Apop-
totic cell percentage was evaluated by flow cytometry, using the
Annexin V-FITC Detection Kit. Error bars indicate standard devi-
ation (SD) from the mean.
showed a cytokine-induced process of actin depoly-
merization. In light of these findings, we came to the
conclusion that the equilibrium between actin poly-
merization and depolymerization processes depends
on the agent's dose and time of stimulation [29]. In our
conditions, there were visible morphological changes
of F-actin organization, but the overall content of 
F-actin was not significantly affected. This may be due
to the fact, that whitin relatively short period of time
after cytokine stimulation, a remarkable fluctuation of
F-actin content could be observed: an initial consider-
able increase, soon followed by a decrease to the orig-
inal level at the next stage [29]. Whereas, in our study
the treatment time was of such an extent, that stimu-
lated cells might be rather in the latter phase with
regard to actin polymerization. Apart from that, a mod-
ifying factor might be obviously the kind of cytokine
used. It was shown that there are some differences
between levels of G-CSF and GM-CSF activity.
Nagler et al. [33] showed different impact of these
cytokines on hematopoiesis in vitro, including greater
granulocitic differentiative and fewer proliferative
potential of G-CSF than GM-CSF in marrow cells. In
our study, the content of F-actin after G-CSF treatment
was slightly increased compared to the relevant level
resulting from GM-CSF activity. In fact, we were not
able to observe any changes of mean fluorescence
intensity, which would be supported by criteria of sta-
tistical significance. However, on the base of morpho-
logical observations, we assume that the prevalence of
F-actin granular over fibrillar structures, visible after
exposure to G-CSF, might reflect a further differentia-
tion phase than it was seen at the same moment, in the
case of GM-CSF treatment. Thus, the effect of G-CSF
seems to be at least slightly stronger than analogical
feature of GM-CSF.
Additionally, as we have mentioned before, HL-60
cell line can differentiate spontaneously and, accord-
ing to this, we observed the network of F-actin not
only around the cell periphery, but also slight fluores-
cence signals in the cytoplasm of control cells
[5,34,35]. Moreover, in our experiment, some nuclei
showed apoptotic features after treatment with GM-
CSF or G-CSF. On the base of this finding, we suppose
that studied cells were subject to the differentiation
process, and consequently they would go on the apop-
totic pathway [36]. However, in our experimental con-
ditions there was still a striking quantitative domina-
tion of cells transited from G1 into S phase over those
representing some apoptotic features. Similarly, it was
noticed by Katagiri et al. [37], that retinoic acid-
induced differentiation of HL-60 cell line was initially
protected against premature apoptotic cell death by
specific protein-tyrosine kinases. Therefore our results
(no statisticaly significant increase in the apoptotic cell
number in comparison with control) may suggest the
existence of similar mechanism during GM-CSF or 
G-CSF treatment in our experimental conditions.  Fur-
thermore, the G1 phase arrest is known as a marker of
cell differentiation, but the lack of functional p53 in
HL-60 cell line might be related to the abrogation of
the G1/S checkpoint in the cell cycle [38,39]. The p53
absence might affect apoptotic susceptibility of studied
cells at this moment of the cell cycle progress as well.
According to this, in the stage of differentiation
analysed by us, there was not only an increase in the
number of cells in the S-phase, but also we were
unable to show statistically significant differences in
the number of apoptotic cells compared to control.   
Besides that, giant cells with enormous nuclei
observed in our study may support presence of an
alternative, non-apoptotic way of the cell death. One of
them is mitotic catastrophe, which appears particular-
ly often in the absence of p53 activity [40]. Since mor-
phological changes accompanying this phenomenon
are similar to these observed by us, we suppose that
such a kind of cellular death could occur in our exper-
imental conditions as well. 
Our observations, concerning the cytokine effect on
F-actin organization and cell cycle progression in the
HL-60 promyelocytic leukemia cell line, showed not
only specific features of this p53-null cell line under
the treatment with growth stimulating factors, but also
raised questions that seem to need further explana-
tions. Regarding the latter, we found that particularly
interesting topics among others were: the low frequen-
cy of apoptosis and the G1 to S phase transition in the
cell cycle, rather unique during the cellular differenti-
ation process, as well as the possible occurence of
alternative cell death mechanisms. As the action of
cytokines may have varying potential effects on
human acute myeloid leukemia cells, morphological
changes in HL-60 cells showed in this study might be
helpful in understanding subtle differences of differen-
tiation programs resulting from G-CSF and GM-CSF
treatment [5].
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